SCL
Stepan Company48.41
+0.21+0.44%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.09BP/E (TTM)
24.45Basic EPS (TTM)
1.98Dividend Yield
0.03%Recent Filings
8-K
10-Q
Q3 FY2025 results
Stepan Company posted Q3 net sales of $590.3M, up 8% y/y from $546.8M, fueled by higher prices passing through raw material costs and a 1% volume bump, though gross profit dipped to $71.0M from $75.7M on softer margins. Operating income fell 9% y/y to $21.8M, with Surfactants down 40% to $15.7M amid startup costs at the new Pasadena facility, yet Polymers held steady at $14.1M and Specialty Products surged 158% to $9.6M on pharma order timing. Diluted EPS landed at $0.47, down from $1.03, matching 22,893K diluted shares with no anti-dilution flags. Cash climbed to $118.5M, free cash flow hit $0.0M (derived from $87.9M operating cash minus $87.9M capex), while total debt rose to $655.5M including $75.0M new 6.17% notes due 2033; revolver availability stood at $116.4M with covenants intact. Assets held for sale in Philippines signal a Q4 exit. Environmental remediation under CERCLA lingers as a persistent drag.
8-K
Q3 net income drops, EBITDA rises
Stepan Company reported third-quarter 2025 net income of $10.8 million, down 54% year-over-year, yet adjusted EBITDA climbed 6% to $56.2 million amid 1% global volume growth and $40.2 million free cash flow. Surfactants sales rose 10% to $422.4 million on higher prices, but EBITDA fell 14% due to Pasadena site start-up costs and raw material spikes; Polymers and Specialty Products showed mixed gains. The board declared a $0.395 per share dividend, payable December 15, marking 58 years of increases. EBITDA grew despite headwinds.
8-K
CFO veteran resigns amicably
Stepan Company announced on October 10, 2025, that Samuel S. Hinrichsen, its Global Vice President of Finance and Investor Relations, will resign effective October 31, 2025, with no disagreements on operations or policies. He had served as interim CFO from October 30, 2024, to July 15, 2025. The company appreciates his contributions. No successor named yet.
10-Q
Q2 FY2025 results
Stepan Company posted solid Q2 FY2025 results, with net sales climbing 7% year-over-year to $594.7M on higher prices and modest volume gains, though foreign exchange headwinds shaved off a bit. Operating income dipped 4% to $18.0M amid a $1.1M EPA penalty and elevated startup costs at the new Pasadena facility, yet Polymers surged 26% on stronger volumes and margins while Surfactants held steady. Diluted EPS rose to $0.50 from $0.42, backed by 22.9M shares; YTD figures align neatly with no dilution quirks. Cash sat at $88.9M against $658.0M debt, including fresh 6.17% notes due 2033, with $139.6M revolver room and FCF negative at -$40.2M (derived) from $58.3M capex. The planned sale of Philippine assets closes later this year. Environmental liabilities loom large under CERCLA, with reserves at $19.5M for remediation sites.
IPO
Website
Employees
Sector
Industry
AVNT
Avient Corporation
30.50+0.02
BCPC
Balchem Corporation
157.10-1.61
CC
Chemours Company (The)
11.69-0.09
CE
Celanese Corporation
40.95-1.54
IFF
International Flavors & Fragran
64.58+0.41
LNXSF
Lanxess Ag
20.00+0.00
SHW
Sherwin-Williams Company (The)
327.87-0.58
SSL
Sasol Ltd.
6.13-0.14
SXT
Sensient Technologies Corporati
93.84-0.26
SYHMY
Synthomer PLC
0.70+0.00